The Consumer Discretionary group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is lululemon athletica (LULU) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Consumer Discretionary sector should help us answer this question.lululemon athletica is a member of our Consumer Discretionary group, which includes 259 different companies and currently sits at #7 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. LULU is currently sporting a Zacks Rank of #1 (Strong Buy).The Zacks Consensus Estimate for LULU's full-year earnings has moved 9.25% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.Based on the latest available data, LULU has gained about 10.13% so far this year. At the same time, Consumer Discretionary stocks have lost an average of 3.57%. This means that lululemon athletica is outperforming the sector as a whole this year.Breaking things down more, LULU is a member of the Textile - Apparel industry, which includes 22 individual companies and currently sits at #27 in the Zacks Industry Rank. Stocks in this group have gained about 9.95% so far this year, so LULU is performing better this group in terms of year-to-date returns.Investors with an interest in Consumer Discretionary stocks should continue to track LULU. The stock will be looking to continue its solid performance. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.See these 7 breakthrough stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report lululemon athletica inc. (LULU): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research